really good argument and in this day and age, "porque no los dos?", why can't we have both ?
Triangle discounted the cardio protect value by 50%, so why can't we have one BP paying 50% upfront, USD5-8B, and the remaining 50%, $5-8B, paid out in royalties on a sliding scale, ie. majority paid out in bisantrene's patent life and less when generics come into play?
same goes for FTO and $1B AML
certainly a lot more digestible...
AbbVie paid USD22B for only 50% of Pharmacyclics and the other 50% was owned by J&J, instos and SHs who enjoyed royalties/divies of some sort
Ann: Race releases complete cardio-protection data & video, page-204
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
0.025(1.53%) |
Mkt cap ! $282.7M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.58 | $350.6K | 215.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 2493 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |